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RAS proteins are small GTPases, which serve as master regulators of a myriad of signaling cascades involved in highly diverse cellular
processes. RAS oncogenes have been originally discovered as retroviral oncogenes, and ever since constitutively activating RAS mutations have
been identified in human tumors, they are in the focus of intense research. In this review, we summarize the biochemical properties of RAS
proteins, trace down the evolution of RAS signaling and present an overview of the spatio-temporal activation of major RAS isoforms. We further
discuss RAS effector pathways, their role in normal and transformed cell physiology and summarize ongoing attempts to interfere with aberrant
RAS signaling. Finally, we comment on the role of micro RNAs in modulating RAS expression, contribution of RAS to stem cell function and on
high-throughput analyses of RAS signaling networks.
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RAS proteins control cellular signaling pathways respon-
sible for growth, migration, adhesion, cytoskeletal integrity,
survival and differentiation. RAS proteins belong to the large
family of small GTPases, which are activated in response to
various extracellular stimuli. For instance, RAS proteins are
activated in response to growth factor stimulation and
subsequently bind to numerous effector proteins leading to
the activation of several signaling cascades within the cell.
Since defects in RAS signaling may result in malignant
transformation, the activation of RAS proteins is tightly
controlled in normal cells. In fact, RAS genes were originally
identified as retroviral oncogenes in the 1960/70s from the
genome of Harvey and Kirsten rat sarcoma viruses [1]. RAS
research has gained momentum in 1980s, when constitutively
activating RAS mutations were identified in human tumors [1].
It is estimated now that approximately 20% of all human tumors
have activating mutations in one of the RAS genes. Therefore,
multiple approaches are undertaken to develop tumor therapies
efficiently targeting RAS and RAS effector pathways. In the⁎ Corresponding author. Tel.: +49 931 201 45141; fax: +49 931 201 45835.
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doi:10.1016/j.bbamcr.2007.01.012past decades, research on RAS signaling has shed a lot of light
on the regulation of RAS effectors, signaling cascades and their
cross talk in modulating various cellular processes. In this
review, we attempt to present an overview of the recent
advances made in the field of RAS biology.
2. Structure and biochemistry of small GTPases
Due to their preeminent role in tumorigenesis, RAS proteins
are the founding members of the superfamily of small GTP
binding proteins, also called RAS-like GTPases or RAS
superfamily of GTP-binding proteins. A common feature of
RAS proteins is that they function in signal transduction across
membranes, in particular in signal transfer induced by growth
factors. Their primary role is to assemble transient signaling
complexes at the membrane that activate signal transduction
pathways coordinating transcription, cell shape and migration,
endocytosis, cell survival and cell cycle progression, differ-
entiation, senescence and more.
The question arises how many RAS family members are
there to fulfill all of these different functions? The main
problem is to define appropriate criteria for the entry of RAS
and RAS-like proteins into this superfamily as well as for their
classification into subfamilies. In general, small G-proteins are
in the range of 20 to 29 kDa, share sequence homologies and
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structure, which is composed of six β-sheets surrounded by α-
helices. More than 150 RAS-like genes have been identified in
mammalian genomes [2,3]. The whole RAS superfamily has
been divided into five subfamilies: RAS, RHO, RAB, ARF
and Gα subunits of heterotrimeric G-proteins [2]. In contrast,
Channing Der and colleagues did not include Gα subunits
under this superfamily and assigned RAN to a distinct RAS
subfamily [3]. Both groups have included RAP, RAL, RHEB
and other GTPases into the subfamily of RAS proteins, which
trigger effector pathways not primarily used by RAS [2,3].
Other classifications rely on the simplistic view that there are
only three true RAS proteins (H-, N-, and KRAS), and
subsume other family members as RAS-like proteins. How-
ever, MRAS, RRAS and ERAS definitely belong to the RAS
subfamily, as they signal through at least one of the RAS
effector pathways, sometimes in a cell type- and/or adaptor-
dependent manner [4–6]. We realize that the classification of
RAS proteins based on homology and function bears many
caveats that have to be re-addressed in future.
Molecular processes underlying the function of RAS as a
binary switch are a paradigm for the whole superfamily of small
G-proteins. They alternate between GTP- and GDP-bound
conformations, where the GTP-bound conformation represents
the “On” and GDP-bound the “Off” state. Upon binding, two
regions of RAS undergo dramatic structural changes depending
on the type of bound nucleotide. These are called Switch region
I (aa 30–38) and Switch region II (aa 59–67) and form an
interaction surface for effector molecules in a GTP-dependent
manner [7], see Fig. 1. The effector loop is a fingerprint of small
GTPases determining the specificity of effector binding to a
given GTPase.Fig. 1. Structural changes in RAS molecules upon nucleotide binding. The
pictures were drawn using RASMOL software [222] and the coordinate PDB
files for RAS–GDP (1Q21; [223]) and pre-hydrolysis RAS–GTP (obtained by
flash photolysis of caged GTP in the crystals, 1QRA; [224]). The peptide chain
is presented as a ribbon, β-strands are in gold, α-helices are red-colored.
Nucleotides are presented as bright yellow stick models, magnesium ions as
green spheres. Phosphate-binding P-loops are depicted in blue. The two switch
regions of RAS molecule undergoing major spatial rearrangements upon GTP
hydrolysis (SW I and SW II) are magenta colored. As an example, the dramatic
relocations of two amino acids in the structure of Switch I (Tyr32 and Thr35) are
shown (arrows). For more details, see text.In the presence of magnesium ions, the association of
guanine nucleotides with small G-proteins is generally very
tight. The dissociation constants of GDP and GTP are in the
picomolar range (KD approximately 10–100 pM) [8], and
therefore G-proteins are usually present in a complex with
either GTP or GDP. Although RAS proteins have a measurable
GTPase activity on their own (GTP hydrolysis rate constant:
0.028 min−1) [9], it is too low to be relevant at the physio-
logical level. This fact implies that transitions between the “On”
and “Off” states of RAS require additional help from
specialized proteins accelerating GTP hydrolysis. These
GTPase accelerators are termed GTPase activating proteins or
GAPs and increase the GTP hydrolysis of RAS by approxi-
mately 100 000 fold [10]. In order to recharge the GTPase, the
binding of GDP must be weakened by the action of guanine
nucleotide exchange factors or GEFs, which catalyze its replace-
ment with GTP.
As will be discussed later, the oncogenic mutants of RAS
have amino acid exchanges predominantly at three residues:
G12, G13 and Q61 [11]. These substitutions prevent the
intrinsic and GAP catalyzed hydrolysis of GTP, thereby gen-
erating permanently active RAS molecules with severe
consequences for the cell. The solution of the crystal structure
of a RAS·GDP·p120GAP complex mimicking the transition state
of GTP-hydrolysis shed light on the molecular basis of the
oncogenicity of activated RAS mutants [12]. Wittinghofer and
coworkers described that the presence of any side chain at
position G12 and partially also at position G13 is preventing the
proper insertion of the catalytic “arginine finger” provided in
trans by RasGAP into a position near the β- and γ-phosphates
of GTP. In complex with wild-type RAS this positive arginine
charge is neutralizing the negative charge, which is required for
the cleavage of the bond between the β- and γ-phosphates. RAS
Q61 is located in the switch II region and is mostly conserved
among small G-proteins and is thought to activate the water
molecule for an attack of the γ-phosphate of GTP. The
relocation and fixation of Q61 in a position suitable for catal-
ysis is responsible for the so-called allosteric part of GAP
activity, which is detected as residual activity in GAP mutants
with a substituted arginine finger [13].
It is worth mentioning that some GTPases of the RAS
superfamily are less addicted to glutamine at positions homo-
logous to Q61. For example, RAP GTPases with threonine at
the Q61 position use the asparagine “thumb” of Rap1GAP,
which takes the role of Q61 [14]. As a second example, GTP
hydrolysis by RAB GTPases with Q61 substituted by leucine is
efficiently accelerated by their cognate GAPs to a degree similar
to wild type proteins. This acceleration is fully dependent on the
presence of the arginine finger [15]. It can be concluded, that
despite similarities in the overall structure and buildup of the
catalytic center, there is no common reaction mechanism for
GTP hydrolysis by small G-proteins [16].
Due to problems with X-ray diffraction of crystallized full-
length proteins, structural studies of RAS proteins have been
done so far only with C-terminally truncated RAS proteins
containing the complete GTPase domain but lacking up to 23 C-
terminal residues. In comparison to their full-length counter-
Fig. 2. Major steps in the evolution of RAS and RAF signaling. The eukaryotic
branch of the tree of life was adopted from http://tolweb.org and [225]. (I) The
compartmentalization of eukaryotic cells into membrane-enclosed organelles
was accompanied by gene duplication and functional diversification of small
G-proteins. (II) Genomic evidence puts the appearance of RAS to a common
ancestor of opisthokonts and slime molds. (III) RAF kinases linking RAS and
MAPK signaling accompanied the development of multicellularity in animals.
For more details, see text.
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biochemical parameters, such as GTP/GDP binding and
hydrolysis [9]. However, the hypervariable C-terminal regions
of RAS proteins are the sites of posttranslational modifications
determining subcellular localization as well as some biological
properties of RAS isoforms (discussed in detail later).
3. On the evolution of small G-proteins
3.1. The early evolution of eukaryotes and the functional
diversification of small G-proteins
RAS signaling seems to be relatively recent in terms of
evolution even if the whole RAS superfamily is considered. The
division into membrane-enclosed sub-compartments dramati-
cally increased the complexity of eukaryotic cells and brought
about a demand for communication and precisely regulated
trafficking between individual compartments. As a result of
multiplication and functional diversification, small G-proteins
became central regulatory units of nearly all aspects of intra-
and intercellular communication [17]. The following processes
are regulated by small G-proteins: import of proteins from the
cytoplasm into the endoplasmic reticulum (ER) by a signal
recognition particle (SRP), whose β-subunit SRPβ is a G-
protein. Vesicle budding as well as coat assembly on the surface
of transport vesicles by Sar and Arf GTPases. In addition,
vesicle docking and targeting are regulated by RAB GTPases,
cytoskeleton and cell shape are under the control of RHO-
GTPases and exchange of proteins and nucleic acids between
nucleus and cytoplasm is governed by RAN GTPase. However,
it should be emphasized that this subdivision based on
functional criteria is only arbitrary and cross talk between
different subfamilies of the RAS superfamily has been
described [18].
3.2. Co-evolution of RAS signaling and intracellular
processing of extracellular signals
One of the most surprising findings in the RAS field is that
none of the so far sequenced plant genomes encoded either RAS
or RasGAP proteins [19], although they are particularly rich in
RAB and RHO-like GTPases [20]. This absence has been
linked to the lack of receptor tyrosine kinases in plants, which
are utilizing a different set of receptor serine/threonine- and
histidine kinases instead [21]. Therefore, it is conceivable that
animals and plants diverged prior to the occurrence of the RAS
signaling module. However, the overall scenario seems to be a
bit more complicated. For example, while baker's yeast Sac-
charomyces cerevisiae possesses two redundant RAS genes,
which are involved in cAMP signaling [22], fission yeast
Schizosaccharomyces pombe contains a single RAS gene, which
was shown recently to signal through two different cascades
depending on its intracellular localization [23]. Amoeba Dic-
tyostelium discoideum contains several RAS proteins regulating
actin assembly and mobility, endocytosis and developmental
patterning [24], but no RAF gene [25]. The genomes of Giardia
and Trypanosoma, primitive unicellular eukaryotes, contain noRAS gene [26], which might be either due to genome reduction
or constitute a further proof of the later origin of RAS.
In metazoans, the major effectors of RAS are RAF kinases
regulating the mitogenic cascade, one of the MAP kinase
cascades. Since multicellular plants also contain MAP kinase
cascades, it may be expected that they also contain RAF as a
MAP kinase regulator. In this scenario RAF would presumably
not be hooked up with a RAS binding domain (RBD) but instead
be outfitted with other regulatory domains. In fact, as many as 52
RAF-related kinases have been identified in the Arabidopsis
genome and have been shown to be significantly divergent at
non-catalytic sequences in comparison to metazoans [27].
Plant genomes, as already mentioned, contain no RAS genes
at all. As expected, we have not been able to detect kinases
bearing regions with a homology to the RBD of RAF by
database analysis of the Arabidopsis genome. This observation
gains further support by genetic analyses of ethylene signaling
in plants, where one of the presumable RAF orthologs, CTR1, is
under the control of the ethylene receptor histidine kinase ETR1
[28]. On the other hand, the large number of proteins containing
a RAF-like kinase domain in early diverged plants supports the
view that the tyrosine kinase-like (TKL) branch of kinases,
including RAF kinases, is of ancient origin.
Taken together, we propose that three major events have
been involved in the evolution of RAS signaling (see Fig. 2). (I)
Functional diversification of G-proteins accompanying sub-
cellular compartmentalization in early eukaryotes. (II) Invention
of RAS at the level of development of opisthokonts/amoebozoa
lineage. In its archaic form, RAS was not feeding through RAF
into the MAP kinase cascade. (III) Gain of a RBD by (one of)
the preexisting RAF-like kinase(s) by domain shuffling and the
appearance of receptor tyrosine kinase signaling in conjunction
with multicellularity in metazoans. This enabled RAF to
become the primary messenger of RAS-mediated signals from
receptor tyrosine kinases to the MEK-ERK pathway in this
lineage. In contrast, although the multicellularity and the
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kinome evolved in parallel to the multicellularity in the animal
kingdom, the final two steps were never performed and
therefore the tyrosine kinase branch of the kinome and RAS
are missing in plants. Instead, other signaling pathways and
signaling molecules have been generated, which led to the
differences in intra- and intercellular signaling observed today.
4. Functional diversity of RAS isoforms by differential
expression, localization and spatio-temporal signaling
4.1. Expression analyses and knock-out studies of RAS
isoforms
The expression analysis of RAS isoforms revealed sig-
nificant variations between tissues as well as during develop-
ment. For instance in mice, HRAS transcripts are highly
expressed in brain, muscle and skin and lowest in liver, while
KRAS transcripts are readily detected in gut, lung and thymus.
NRAS transcripts are primarily expressed in the testis and
thymus [29]. Differential expression is also observed during
mouse development where NRAS expression is high at day 10
of gestation and the expression of KRAS is reduced during the
end of gestation [30]. These descriptive analyses clearly
suggested that the three isoforms of RAS perform distinct cell
type and tissue specific functions. Mouse knock-out studies
revealed an obligatory role for K- but not H- or NRAS during
mouse development [31–34]. While mice deficient for HRAS
or NRAS lack any obvious phenotype, KRAS mutated mice
developed embryos, which died between 12 and 14 days of
gestation, with fetal liver defects and evidence of anemia. The
phenotype observed in KRAS mutant mice may be attributed to
the predominant expression of this isoform in a critical cell type
(e.g. within the fetal liver) [32].
4.2. Differential activation and localization of RAS isoforms
Another line of evidence often considered for individual
roles of RAS isoforms pertains to the analysis of constitutively
activating RAS mutations in human cancer. Though the mutated
forms of the three RAS genes produce the same phenotype in in
vitro transformation assays [35], the oncogenic forms of K-, H-,
and NRAS are preferentially detected in specific tumor types.
For example, KRAS mutations occur primarily in colon and
pancreatic cancers, NRAS mutations are often detected in
myeloid leukemia and HRAS mutations are high in bladder
carcinomas [35]. The isoforms display very high degree of
sequence homology and the major differences are confined to
the hypervariable region (HVR), at the C-terminus. The HVR
encompass approximately 25 aa, which are required for the
posttranslational modifications that direct plasma membrane
anchoring as well as trafficking of newly synthesized RAS
proteins to the inner surface of the plasma membrane from the
cytosolic surface of the ER [36]. The first modification
described for RAS was the attachment of a 15-carbon isoprenyl
group to C186 by farnesyl transferase, which is irreversible and
accompanied by cleavage of the three C-terminal amino acidsand subsequent carboxymethylation of the C-terminal cysteine.
Farnesylation is found in all RAS proteins and is essential for
their biological function [37]. However, it has been shown that
the C-terminal farnesylation does not suffice for proper
targeting of RAS to membranes. Each of the three prototype
RAS proteins (H-, N-, and KRAS) undergoes additional
modifications. Whereas HRAS is palmitoylated on C181 and
C184, NRAS is palmitoylated on C181 and KRAS4B does not
have any palmitoylation at all. Instead, KRAS4B possesses the
so-called polybasic region, a stretch of lysines, which are
believed to interact with negatively charged head groups of
plasma membrane lipids. While palmitoylated H- and NRAS
enter the exocytic pathway through Golgi to reach the plasma
membrane, KRAS4B bypasses the Golgi. The trafficking of
alternatively spliced KRAS4A is believed to follow H- and
NRAS as this splice variant lacks the polybasic domain and as it
is palmitoylated at C180. The key enzyme responsible for
palmitoylation of H- and NRAS is RAS palmitoyl transferase
(RPT), which was cloned from S. cerevisiae [38]. The various
stages of RAS modification and intracellular trafficking are
summarized in Fig. 3.
Recent studies with live cell imaging, fluorescent resonance
energy transfer (FRET), fluorescent recovery after photo-
bleaching (FRAP), electron microscopy (EM) and single
particle tracking analysis (SPT) have shed more light into
the dynamics of RAS proteins and their interactions with
membranes [36]. These studies revealed that RAS generates
signal outputs when associated with non-plasma membranes as
well. Interestingly, differences in the HVR directed RAS
proteins to different microdomains of the plasma membrane.
The plasma membrane, which was long considered to be a
uniform lipid bilayer, has turned out to constitute a complex
mosaic of microdomains with various compositions of proteins
and lipids [39]. Palmitoylation of RAS isoforms may increase
their membrane affinity so that they can be captured by the
exocytotic pathway to the trans Golgi and subsequently be
sorted to the various plasma membrane microdomains.
Association of non-palmitoylated RAS is detected in the ER
by live cell imaging, although the association is weak and can
be dislodged by hypotonic lysis of cells [40,41]. In contrast to
H- and NRAS, KRAS4B cannot be detected at the Golgi and
has been shown to interact with microtubules via the polybasic
domain. In addition, prenylation and methylation of KRAS4B
is also required for this interaction [42,43]. In addition, the two
palmitoylated RAS proteins were shown to undergo ubiqui-
tination and are subsequently targeted to endosomes, a cellular
localization that prevents them from activation of the MAP
cascade [44].
4.3. Spatio-temporal activation of RAS
The spatio-temporal activation of RAS isoforms and their
downstream signaling cascades is highly influenced by their
distinct microdomain localization within the plasma membrane.
A heterogenous mixture of lipids and proteins leads to the
organization of various microdomains of which lipid rafts and
caveolae are well characterized [39]. These microdomains serve
Fig. 3. Modifications and localization of RAS proteins. RAS proteins are synthesized in the cytosol and farnesylated by proteinfarnesyl transferase (PFT) at the
cysteine residue of the CAAX motif (A is an aliphatic amino acid and X is any amino acid). The cleavage of AAX tripeptide and methylation occurs at the cytosolic
surface of the ER and are mediated by RAS converting enzyme 1 (Rce 1) and Isoprenylcysteine carboxylmethyl transferase (Icmt), respectively. H- and NRAS further
undergo palmitoylation in the hypervariable region (HVR) on the Golgi to reach the plasma membrane via vesicular transport, while KRAS reaches the plasma
membrane by a yet uncharacterized pathway. Depalmitoylation of H- and NRAS will lead to the localization of these two isoforms in the Golgi.
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of specific signaling proteins to these structures confers
specificity and intensity of signaling processes. Quantitative
EM analysis of intact plasma membrane sheets revealed that
neither HRAS nor KRAS are particularly localized in the
caveolae, although some of the downstream RAS effectors have
been detected there [45,46]. In fact, most of the RAS proteins
were found in non-raft part of the plasma membrane. For
instance, KRAS is predominantly not associated with lipid rafts
irrespective of its activation status. GTP-HRAS is also primarily
localized outside lipid rafts, whilst 50% of GDP-HRAS is
detected in the caveolae [46]. Based on these results, it has been
proposed that HRAS is in a dynamic equilibrium between the
lipid raft and non-raft microdomains of the plasma membrane, a
process which is regulated by GTP loading.
The localization of H- and KRAS to plasma membrane
microdomains is not disrupted by cholesterol depletion
suggesting that both isoforms function in non-raft microdo-
mains, also called nanoclusters in the plasma membrane. A
recent study by Hancock and colleagues revealed that the two
palmitates of HRAS have distinct biological roles. While
monopalmitoylation of C181 can efficiently target HRAS to
plasma membrane, it fails to segregate HRAS from cholesterol
rich to cholesterol independent microdomains. On the other
hand, monopalmitoylation of C184 does not permit efficient
trafficking beyond the Golgi apparatus, although this mutant
once in the plasma membrane can segregate HRAS from rafts to
non-raft microdomains upon GTP loading [47]. NRAS alsoseems to exhibit GTP dependent changes in its localization like
HRAS as GTP loaded NRAS is predominantly localized to lipid
rafts, while the GDP loaded form is primarily confined to the
non-raft microdomains [47]. In addition to the modifications in
the anchor region and the activation state, the linker domain of
the HVR also contributes to the HRAS microlocalization as
deletion of this domain confines HRAS primarily to lipid rafts
[48].
Apart from these modifications, additional proteins interact-
ing with RAS are also modulating the microlocalization of RAS
isoforms. For instance, the lectin galectin-1 interacts strongly
with activated HRAS and to a lesser extent with KRAS but not
with NRAS or inactive K- or HRAS. Downregulation of
galectin-1 inhibits cellular transformation with G12V HRAS,
while overexpression of galectin increases the size of G12V
HRAS clusters leading to increased activation of the MAPK
pathway [49,50]. Galectin-3, which is expressed frequently in
human tumors, specifically binds to activated KRAS4B and
stabilizes GTP-KRAS by reducing the efficiency of p120GAP-
mediated GTP hydrolysis [51]. Another protein that interacts
with the C-terminus of HRAS is Phosphodiesterase δ (PDEδ). It
binds more strongly to GDP- than GTP-HRAS and when
ectopically expressed results in the redistribution of HRAS from
the plasma membrane to the cytosol [52]. Moreover, scaffolding
proteins also influence coupling of active RAS with its
effectors. For instance, leucine rich repeat protein Sur-8
interacts with active RAS and RAF and induces MAPK
activation [53].
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The first indication that RAS/MAPK signaling occurs in
membranes apart from the plasma membrane was the detection
of Shc, Grb2–SOS and phosphorylated RAF in the endosomal
fraction isolated from cells after EGF treatment [54]. These
observations were subsequently supported by expression of the
dominant-negative K44A mutant of dynamin, which blocked
the activation of ERK induced by G-protein coupled receptors
[55] as well as neurite outgrowth in response to NGF in PC12
cells [56]. As endosomes are derived from the plasma
membrane, the observation of transmission of signaling
complexes from the plasma membrane to the endosomes was
not surprising. The presence of a significant pool of H- and
NRAS in the Golgi raised the possibility that RAS/MAPK
signaling may indeed take place in this organelle. Using a
fluorescently labeled RAF-RBD Chiu et al. demonstrated the
activation of RAS at Golgi and plasma membrane [57]. While
the activation of RAS at the plasma membrane was transient,
activation of RAS at the Golgi was delayed and sustained [57].
In addition, RAS-GRP, a RAS GEF (discussed below),
localized to Golgi and seems to be responsible for the activation
of RAS in this compartment. The acylation/deacylation cycle of
RAS also contributes to the activation of RAS at this organelle
[58]. For example, expression of palmitoylation-deficient
mutants of H- and NRAS provoke their accumulation in the
ER and cytosol [41]. Components of RAS/MAPK have also
been reported on mitochondria. The localization of Ras and its
effectors in the mitochondria are discussed in detail in an
accompanying review.
Besides subcellular localization, the intensity and duration of
RAS signaling profoundly influence downstream signaling
networks and the final signal output [59,60]. One of the finest
examples we would like to highlight here are the studies
performed with the rat PC12 pheochromocytoma cells [60].
When treated with NGF, PC12 cells express neuronal markers
and show neurite outgrowth. However, when treated with
insulin or EGF, they show only a weak proliferative response.
Though both receptors activate RAS, the timing of RAS/MAPK
activation with both the receptors was different. While treatment
with EGF leads to a transient activation of ERK, treatment with
NGF caused a sustained RAS/MAPK activation leading to
differentiation of these cells. These observations have also been
attributed to the sustained activation of Rap1b with NGF but not
with EGF [61,62].
4.5. RAS GEFs
As mentioned above, the activity of RAS proteins is tightly
controlled by switching between the GDP- and GTP-bound
states. Although RAS proteins possess intrinsic GTP-ase
activity, regulatory proteins like guanine nucleotide exchange
factors (GEFs) and GTPase activating proteins (GAPs)
profoundly influence the activation of RAS. As the cellular
amount of GTP is tenfold higher than GDP, GEFs promote the
formation of active GTP–RAS, while GAPs stimulate the
intrinsic rate of GTP hydrolysis and thereby the formation ofGDP-RAS. Oncogenic RAS mutations at residues G12, G13
and Q61 render them constitutively active (GTP–RAS) as they
are impaired in their intrinsic and GAP-mediated GTP
hydrolysis. Three main classes of RAS GEFs are currently
known with a common CDC25 homology catalytic domain and
an N-terminal RAS exchange motif: SOS, RAS-GRF and RAS-
GRP. SOS and RAS-GRF also serve as GEFs for Rac GTPases.
The role of SOS in receptor tyrosine kinase-mediated
activation of RAS is very well established. SOS, in addition
to the SOS homology domain encompasses a Dbl homology
(DH) domain and pleckstrin homology (PH) domain. The DH
homology domain mediates the GDP/GTP exchange on Rho
GTPases, while the PH domain is responsible for membrane
localization. In resting cells, SOS is primarily found to be
associated with the Src homology 3 (SH3) domains of the Grb2
adaptor protein and upon receptor stimulation the Grb2–SOS
complex is recruited to the plasma membrane. This recruitment
is primarily mediated by the interaction of the SH2 domain of
Grb2 with the tyrosine phosphorylated residues in the
cytoplasmic domain of the activated receptor or to the tyrosine
phosphorylated Shc, another adaptor protein implied in this
process [63]. This association with the activated receptor brings
SOS to the vicinity of RAS leading to the formation of GTP–
RAS. Grb2–SOS complex is also utilized by G protein coupled
receptors to activate RAS through Ca2+ dependent activation of
PYK2 [64]. Recent structural studies suggested RAS–GTP as
an allosteric activator of SOS. Binding of RAS–GDP to the
distal allosteric site in SOS reduced the activity of SOS, while
binding of RAS–GTP to this site enhances the activity of SOS
[65,66].
RAS–Guanine Nucleotide Releasing Factors or RAS–GRFs
are also members of the GEF family [67]. RAS–GRFs share
80% homology and have a common modular structure: C-
terminal guanine nucleotide exchange domain with the DH and
PH domains in the center of the protein. In addition, an IQ
domain (short calmodulin-binding motif containing I and Q
residues) is present at the N-terminus and required for
activation. RAS–GRFs act on H-, N- and KRAS as well as
on RRAS, and the RAS–GEF activity of these proteins is
triggered by the association of Ca2+-Calmodulin with the IQ
domain. Studies with grf-1 or grf-2 deficient mice revealed that
both RAS–GRF1 and RAS–GRF2 function in coupling of N-
methyl-D-aspartate glutamate ligand-gated ion channel recep-
tors to the activation of MAPK signaling in the neurons of adult
mice [68,69].
RAS guanine nucleotide releasing proteins or RAS–GRPs
are additional members of the GEF family and were initially
cloned from brain and lymphoid tissues [70,71]. RAS–GRPs,
also called CalDAG-GEFs, constitute a group of GEFs
possessing calcium and diacylglycerol binding domains and
can be triggered by diacylglycerol and phorbol ester. RAS–
GRPs also associate with endomembranes and activate RAS.
For instance, GRP1 and GRP3 localize to Golgi thereby
activating Golgi-associated RAS [72], while RAS–GRP2
activates K- and NRAS [73]. DAG binding recruits RAS–
GRPs to plasma membrane. RAS–GRP1-defecient animals
showed impaired T-cell development and impaired T-cell
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mice were severely compromised in integrin signaling and
displayed increased bleeding [75].
4.6. RAS GAPs
p120GAP was the first identified member of the GAP family.
In addition to the catalytic domain, this protein also harbors
SH2, SH3 and PH domains and phospholipid binding motifs.
RAS–GAP was the first protein found to interact with the so-
called effector domain of RAS [76]. Consequently, RAS–GAP
was originally perceived as a major RAS signal terminator.
Indeed, initial evidence suggested that RAS–GAP is in a
complex with receptor and non-receptor tyrosine kinases
[77,78]. However, in contrast to GEFs, there are only a few
details known with respect to pathways modulating RAS–GAP
activity. Yang et al. demonstrated that the partial cleavage of
RAS–GAP by caspase-3 is required to activate AKT leading to
cell survival under mild stress conditions [79]. Neurofibromin,
another RAS–GAP, acts as a tumor suppressor gene and it is
lost in the autosomal dominantly inherited disorder neurofi-
bromatosis type 1 (NF1). Intracellular levels of neurofibromin
have been shown to be dynamically regulated by the ubiquitin–
proteasome pathway [80]. Degradation is rapidly triggered in
response to growth factors and requires sequences adjacent to
the catalytic GAP-related domain of neurofibromin. However,
whereas degradation is rapid, neurofibromin levels are re-
elevated shortly after growth factor treatment. Accordingly,
NF1-deficient mouse embryonic fibroblasts exhibit an
enhanced activation of RAS, prolonged RAS and ERK
activities, and proliferate in response to sub-threshold levels
of growth factors. Recent evidence suggests a crucial role for
NF1 in the activation of mTOR, an evolutionarily conserved
serine/threonine protein kinase that regulates cell growth and
proliferation in yeast, flies, and mammals. mTOR is constitu-
tively activated in cells derived from NF1-deficient mice and
this aberrant activation depends on the phosphorylation of
tuberin by activated AKT [81]. Additional RAS–GAPs have
been identified and their mode of activation has been
characterized. The Ca2+-promoted RAS inactivator CAPRI
was identified as a RAS–GAP stimulated by elevated
intracellular Ca2+ levels leading to attenuation of RAS
activation and MAPK activity [82]. Another member of the
GAP1 family responding to Ca2+ spikes is RAS GTPase-
activating-like RASAL, which is highly expressed in follicular
cells of the thyroid and the adrenal medulla [83]. RASAL
oscillates between the cytosol and the plasma membrane in
response to Ca2+ spikes thereby decoding the complex Ca2+
oscillations into a dynamic regulation in the activation of RAS
[84].
Finally, GAP1 IP4BP and GAP1m are other members of this
GAP1 family with a PH domain. GAPIP4BP is constitutively
associated with the plasma membrane mediated by PIP2
binding, the RASGAP activity is regulated by Inositol
1,3,4,5-tetrakiphosphate [85]. GAP1m is localized to the
perinuclear region of the cytoplasm and upon activation of
PI3K gets recruited to the plasma membrane by PIP3 binding[82,86]. SynGAP, is another member of this family, which is
selectively expressed in the brain and is highly enriched at
excitatory synapses [87]. SynGAP regulates synaptic plasticity
and MAPK signaling in neurons [88]. In the following we will
discuss individual RAS effector pathways after a brief comment
on the historical events leading to the discovery of RAF as the
first RAS effector.
5. RAS and the mitogenic cascade, brief history
In the mid 1980s, several labs [89–92] explored the
connection between growth factor/cytokine signaling and
intracellular oncoproteins by growth factor abrogation experi-
ments with cells that specifically depend on a particular factor
for growth and survival. Gene transfer experiments with
retroviruses and different classes of oncogenes alone or in
combination were subsequently used to establish the broad
scheme of signal transduction cascades connecting cell surface
receptors with cell cycle progression, differentiation and cell
survival processes [92,93]. A hierarchical sequence was drafted
that had protein tyrosine kinases on top followed by RAS
GTPases, RAF serine/threonine kinase and oncogene class
transcription factors, such as Myc, AP1 and Ets. Later, we found
that MAP kinase, another serine/threonine kinase, was also
constitutively active in v-Raf transformed NIH 3T3 cells
leading to the identification of the RAF–MEK–ERK segment
of the mitogenic cascade [94] thereby placing Myc, AP1 and Ets
downstream of MAP kinase. The discovery of RAF as an
effector and the observations leading to the discovery are
discussed below.
6. RAS effectors
RAS effectors are defined as proteins with a strong affinity to
GTP–RAS, whose binding is impaired by mutations within the
core effector domain. The binding of RAS effector proteins to
GTP–RAS triggers distinct signaling cascades. However, the
notion that GDP–RAS does not have any functional role has
been challenged by the recent observation that GDP–RAS
indeed interacts with several effector proteins and modulates
downstream signaling events. For instance, GDP–RAS binds to
the transcription factor Aiolos, thereby modulating the nuclear
translocation of Aiolos and the expression of anti-apoptotic
protein BCL-2 [95,96]. In 1993, RAF kinase was first
discovered as a RAS effector followed by Ral guanine
nucleotide dissociation stimulator (RalGDS) and phosphatidy-
linositol 3-kinase (PI3K). Apart from RAF, PI3K, RalGDS and
p120GAP the growing family of RAS effector proteins includes
Rin1, Tiam, Af6, Nore1, PLCε and PKCζ. Currently there are
more than 10 different RAS effectors (see Fig. 4), and several of
them contain functionally related isoforms [97]. RAS effector
proteins are characterized by the presence of a putative RAS
binding domain or RBD. At least three distinct RBDs are
recognized: (1) the RBD of RAF and TIAM 1, (2) the RBD
from PI3K, and (3) the RAS association (RA) domains of
RalGDS and AF6. The structures of the four RBDs solved so far
displayed the same topology, the ubiquitin fold (ββαββαβ),
Fig. 4. RAS and RAS effector pathways. GTP–RAS binds to numerous effectors
to trigger various signaling cascades, which in turn modulate different cellular
processes ranging from cell growth, survival, cell migration, differentiation and
death. For more details, see text.
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effectors [98].
6.1. RAF and the MEK/ERK cascade
More than 24 years ago, Ulf R. Rapp and colleagues cloned
an oncogene acquired by the murine retrovirus 3611-MSV that
was generated by targeted retroviral transduction [99]. Since
3611-MSV induced rapidly growing fibrosarcoma in mice, the
transduced oncogene was named v-raf and the cellular
homologue was called c-raf-1 (-2 and higher numbers designate
pseudogenes) [99]. Later, Klaus Bister and coworkers demon-
strated that the naturally occurring avian retrovirus Mill-Hill
No. 2 (MH2) carried a second cell-derived sequence besides
myc, which was named v-mil after the virus [100]. By direct
sequencing of both viral genomes, it was later proved that 3611-
MSV and MH2 have integrated orthologues of the same gene
into their genomes [101]. Homologues of C-RAF were also
identified in Drosophila melanogaster (D-RAF) and Caenor-
habditis elegans (lin-45). Two related RAF genes A-RAF and
B-RAF were subsequently cloned. B-RAF appears to be the
founder of the family and the orthologue of D-RAF. All three
RAF isoforms share two conserved regions, CR1 and CR2, at
the N-terminus, while a third conserved region CR3, encodes
the kinase domain at the C-terminus. In regard to RAS/RAF
function, the role of RAS as a signal transducer downstream of
growth factor receptors was suggested by the observation that
epidermal growth factor increases the amount of GTP–RAS and
that microinjection of a monoclonal antibody to RAS blocked
serum induced DNA synthesis [102]. The RAS block was
relieved by the cytoplasmic oncoprotein MOS and the candidate
downstream serine/threonine kinase effector RAF [103]. These
findings left open whether RAF kinases function downstream or
parallel to RAS and whether, in case of a downstream
connection, the interaction was direct or indirect. The following
lines of evidence pointed to a direct effector function of RAFthat was first presented in public by Ulf R. Rapp at a NATO
conference in Spetsai in August 1992 (mentioned in [104]).
(1) Antisense and dominant-negative RAF blocked transfor-
mation by RAS oncogenes in culture [105]. Dominant-
negative RAF mutants included a kinase dead version of
full-length RAF aswell as a more potent fragment of 257 aa
N-terminal fragment called RAF-C4, which encompasses
the cysteine rich domain (CRD). Point mutation within the
CRD abolished the dominant-negative effect of RAF-C4,
and the synergistic interaction between RAS and full-length
RAF as examined in transformation or receptor gene assays
[106].
(2) RAS was shown to activate RAF following growth factor
induction of NIH 3T3 cells and NGF induction of PC12
cells and this activation was blocked with a dominant-
negative RAS (M17 RAS [107]).
(3) Protein kinase Cα (PKCα), which is being activated at the
plasma membrane was observed to phosphorylate RAF
[108].
(4) As activation of PKC and of RAS occurs at the plasma
membrane, whereas RAF shows cytosolic staining, and
because RAS was thought to be a timer of direct protein–
protein interactions (Dieter Gallwitz, personal commu-
nication), RAS was proposed to bring (translocate) RAF
to the plasma membrane into the neighborhood of active
PKC. Based on these findings Rapp et al. proposed in
1992 that RAF and a lipid-derived cofactor directly
interacted with RAS at or near the CRD [104]. In contrast,
the prevailing view at the time was that RAS–GAP had
hallmarks of a RAS effector [109,110], and no other
candidates were seriously considered. To evaluate the
question as to the nature of a link between RAS and RAF
we settled on a collaboration with Joe Avruch's laboratory
leading to a report in the spring of 1993 on “p21-Raf bind
to the amino terminal regulatory region of c-raf1” [111].
The question about lipid cofactors was advanced by the
finding that phosphatidyl serine binds to the CRD and
recently we deciphered that the farnesyl moiety of RAS
also has to interact with this domain of C-RAF for
efficient RAS/C-RAF coupling to take place at least in
vitro and probably also at the membranes. Farnesyl
interaction with the CRD is thought to be required for
transmission of a conformational activation signal to the
RAF kinase domain ([112] and Fischer A, HekmanM and
Rapp UR, unpublished observations).
In 1993, four groups reported that RAF specifically interacts
with activated GTP–RAS proteins [111,113–115]. The paper
by Moodie and coworkers was published a month before the
others [113]. This paper had been inspired by the membrane
translocation hypotheses proposed by Ulf R. Rapp, which he
had brought up in personal discussions with Weber during a
seminar at the NCI in Frederick in fall 1992, an incident that
Weber acknowledged at a AACR symposium on “Oncogenes
and Antioncogenes in Differentiation, Development and
Human Cancer” in Big Sky Resort, Montana, that they both
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data that subsequently appeared in the Science paper. Weber, in
his seminar at NCI had favoured the idea of a “chaotic signaling
network” that did not work with vectorial signal transfer
modules.
Although it is still too early to come up with a final
assessment of receptor/RAS-mediated assembly of signaling
complexes at the plasma membrane, the current view of the role
of the mitogenic cascade clearly involves the use of building
blocks in specific combination and sequence. Much of the
regulation lies in fact on the assembly process (RAS–RAF–
MEK–ERK) at the site of receptor activation in the membranes,
where the activation of signaling through the cascade may be
triggered by the successful assembly of parts docking on each
other with the assistance of scaffolding proteins [116].
Localization of MAP kinase signaling to these membrane
sites is probably not only required for the integration of
transcriptional activity in the nucleus by the mobile effector
kinase ERK, but also for dynamic membrane processes and
cytoskeletal rearrangements that are involved in endocytosis
and cell migration (discussed in other chapters).
Later on, studies from several groups revealed that the RAS
isoforms activate RAF with various intensities. For instance,
Voice et al. demonstrated that KRAS is the most potent activator
of C-RAF followed by N- and HRAS [117]. The RAF–RBD
has been extensively studied by various groups to understand
the spatio-temporal activation of RAS, as already discussed
above [58,118]. In unstimulated cells, C-RAF is inactive and to
a large extent localized in the cytosol. Upon RAS activation,
RAF undergoes conformational changes, phosphorylation and
hetero-oligomerisation leading to its full activation at the
plasma membrane. The ability of RAS to activate C-RAF is
regulated by binding of other proteins like 14-3-3 and prohibitin
to C-RAF[119–121]. The authors would like to refer to
accompanying reviews as well as recent ones on RAF kinases
for detailed information [122,123].
6.2. PI3K
In addition to RAF, the interaction of PI3K with RAS and its
role in various cellular processes have been thoroughly
characterized. In its active form, PI3K is composed of a
regulatory p85 subunit and a catalytic p110 subunit. In 1991,
Lapetina and coworkers reported the association of PI3K
activity with RAS, while the direct interaction of the catalytic
subunit of PI3K with active RAS was demonstrated by Julian
Downward and colleagues [124,125]. PI3K encompasses an
RBD domain for interaction with active RAS, and the structure
of the PI3K–RBD was solved either alone or in combination
with RAS [98]. Among the RAS isoforms, HRAS was
identified to be a more potent activator of the PI3K in
comparison to KRAS [126]. Upon activation of PI3K the
second messenger lipid phosphatidylinositol (3,4,5) tripho-
sphate or PIP3 is generated. PIP3 recruits phosphatidyl inositol-
dependent kinase 1 (PDK1) and PKB/AKT to the plasma
membrane, where PDK1 phosphorylates and activates AKT
[127–129]. Three major isoforms of AKT are recognized:AKT1, AKT2 and AKT3. While AKT1 promotes cell
proliferation and survival, AKT2 is associated with insulin-
mediated metabolic processes. AKT3 deficient mice have
reduced cell size and cell number suggesting a crucial role of
AKT isoforms in modulating cell death and proliferation [129].
Some of the initial evidence for the contribution of PI3K to
malignant transformation was the discovery of amplification of
genes encoding the P110 subunit of PI3K and AKT2 in ovarian,
breast and pancreatic cancer [130]. The high activity of PI3K in
tumor cells is attributed to the loss of the phosphatidylinositol 3
kinase phosphatase with tensin homology or PTEN lipid
phosphatase. PTEN catalyzes the removal of the D3 phosphate
from PIP3 to terminate downstream signaling, and is now
thought to be the most commonly mutated tumor suppressor in
humans, after p53 [127].
6.3. Ral GEFs
RAL (RAS-Like) family GTPases were identified on the
basis of their sequence homology to RAS. Two RAL genes,
RALA and RALB, are ubiquitously expressed in humans and
share 80% homology. RAL–GEFs serve as a link between the
RAS and the Ral family of GTPases. Four distinct RAL–GEFs
have been identified as effectors of RAS with RA domains:
RalGDS, RGL, RGl2/Rlf and RGl3 [97,131]. Initial studies
with NIH 3T3 fibroblasts suggested a minor role for RAL–
GEFs during transformation. However, recent studies revealed a
crucial role for RAL–GEFs in the transformation of human cells
[132]. While activation of RAF alone was sufficient for RAS-
mediated transformation of NIH 3T3 fibroblasts, activation of
this pathway alone did not transform human BJ fibroblasts,
MCF-10A human breast epithelial cells or RIE rat intestinal
epithelial cells [132]. These data suggested that species and/or
cell type specific differences for RAS induced transformation
exist. These observations led Weinberg and colleagues to
decipher the requirements for transformation of various human
cell types. They demonstrated that immortalized HEK cells
require the specific activation of RAL–GEFs and PI3K but not
RAF for transformation in vitro and anchorage-independent
growth [132]. These observations demonstrated the crucial role
of RalGEFs in human cell transformation. Furthermore, White
and colleagues provided evidence for the role of RAL–GEFs in
tumor cell growth and cell survival. By applying an RNA
interference-mediated loss of function approach, they demon-
strated that RALA is required for the anchorage-independent
proliferation of transformed cells, while RALB is required for
the survival of the transformed but not normal cells [133]. RAL
signaling has also been implicated in the regulation of
endocytosis or excocytosis, actin organization, cell migration
and gene expression [131,134–136].
6.4. Tiam
T lymphoma invasion and metastasis protein 1 (Tiam 1) was
identified in a retroviral insertional mutagenesis screen for
genes conferring invasiveness to otherwise non-invasive murine
T-lymphoma cells [137]. Furthermore, Tiam1 was characterized
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thereby linking the activation of RAS to RAC [138]. The role of
Tiam in the RAS–RAC cross talk is further confirmed by the
studies in Tiam1-deficient mice. Tiam1−/− mice were resistant
to the development of RAS-induced skin tumors initiated with
7,12-dimethylbenzanthracene and the fibroblasts derived from
them were resistant to foci formation by oncogenic RAS [139].
Tiam1 was also implied recently in neurotrophin induced
Schwann cell migration [140,141]. In addition to RAS, Tiam1 is
also involved in Rap-1 mediated cell spreading [142].
Membrane localization of Tiam1 is crucial for its ability to
induce Rac-mediated membrane ruffles and activation of JNK.
The intracellular localization and activation of Tiam1 is
modulated by N-terminal myristoylation, phosphorylation and
phosphoinositol binding (for review [143]).
6.5. RASSF
RASSF (RAS association domain family) proteins are a
family of RAS effectors with a RA domain without catalytic
function. RASSF family members have been shown to function
as tumor suppressors as supported by the loss of expression of
RASSF family members in a variety of human tumors
[144,145]. RASSF1 was first identified as a candidate tumor
suppressor gene situated on chromosome 3p21.3 and is
frequently inactivated by DNA methylation [145]. Addition-
ally, overexpression of RASSF proteins provoked anti-
proliferative and pro-apoptotic responses. RASSF2 and
RASSF4 specifically interact with KRAS to induce cell cycle
arrest and induce apoptosis [146,147]. In addition, RASSF2
was identified as a novel tumor suppressor in colorectal tumors
and its expression was silenced by DNA methylation [148].
The idea that epigenetic inactivation of RASSF2 plays a key
role in KRAS mediated transformation is supported by the
findings that KRAS/BRAF mutations were identified more
frequently in colorectal tumors with methylation of RASSF2.
In addition, methylation of RASSF2 was also detected in
colorectal tumors without RAS/BRAF mutations suggesting
silencing of RASSF as a crucial event of colorectal tumori-
genesis [148]. A recent study from Neel and colleagues
suggested a role of RASSF1A for death receptor induced BAX
conformational changes leading to permeabilization of mito-
chondrial outer membranes and apoptosis [149]. This pro-
apoptotic effect of RASSF1A is accomplished by a complex
formation with a BH-3 like protein MAP-1. Interaction with
RASSF1A promotes binding of MAP-1 with BAX leading
the activation of BAX [149]. Ectopic expression of RASSF5
(also called NORE1) induced apoptosis in a RAS dependent
manner and impaired the ability to grow in soft agar [146].
Khokhlatchev and colleagues demonstrated the involvement of
RAS–Nore–Mst1 (mammalian ste20-like kinase) complexes in
apoptotic processes [150].
6.6. RIN and PLC
RIN1 is a RAS effector with RA domain and it functions as a
GEF for Rab5/Vps21 like proteins thereby facilitating RASregulated endocytosis [151]. Three family members are known:
RIN1, RIN2, and RIN3. Whereas RIN1 is primarily cytosolic,
RIN2 and RIN3 are localized to endocytic vesicles.
PLC was originally identified as a RAS binding protein in a
yeast two hybrid screen performed with Let-60 (RAS encoding
gene in C. elegans) as a bait [152]. Cloning of human and rat
homologues of PLC210, designated PLCε, revealed its domain
structure with a RAS GTPase binding domain. PLCε has been
shown to be activated by growth factors like PDGF and EGF in
a RAS and RAP1 dependent manner [153,154]. For instance,
rapid activation of PLCε by PDGF is mediated by RAS, while
sustained activation of PLCε is mediated by Rap1 [154].
PLCε−/− mice showed a delayed onset and markedly reduced
incidence of carcinogen-induced skin squamous tumors. These
data confirmed the crucial role of PLCε in the progression of
carcinomas [155].
6.7. AF6 and PKCζ
The growing family of RAS effectors also include AF6 and
PKCζ which are implied in various cellular processes such as
cell adhesion and transcription, respectively [156–159]. AF6
(also called Afadin) was cloned as an interacting partner of
ALL-1 gene from leukemia's [160], an actin binding protein
with two RA domains in its N-terminus and a PDZ domain,
which assists in interacting with tight junction protein ZO-1
[161]. Consequently, AF6 was found to colocalize with ZO-1
at the tight junctions and gene inactivation studies in mouse
revealed a crucial role of AF6 in maintaining epithelial cell–
cell junctions and cell polarity [156]. AF6 has also been
shown to negatively regulate Rap1 mediated cell adhesion
[157]. PKCζ is similar to RAF in structure and it was shown
to be required during oocyte maturation in Xenopus [162].
Moscat and colleagues demonstrated direct interactions
between RAS and PKCζ in vitro and in vivo [162]. The
various roles of PKCæ have been comprehensively discussed
in a recent review [163].
Putting together, there are a large number of RAS effectors
that perform versatile roles in response to various stimuli. As
mentioned before, activation of various receptors such as
GPCRs, RTKs and integrins by different ligands leads to the
activation of RAS, which can then transmit highly diverse
signals by binding to several effectors. Many of the divergent
signaling pathways initiated by RAS exhibit significant cross
talk, which may finally converge at some level to confer a
specific phenotype. For instance, the activation of RALGDS
can lead to the activation of RAF under some conditions via
PLD [164]. In case of growth factors, activation of RAS alone
could suffice to bring about most if not all of the phenotypes in
the recipient cells. For instance, RAS activation can lead to the
activation of RAB5 via RIN1 leading to endocytosis, which is
definitely required for EGFR signaling to ensue. Along the
same line, by triggering the activation of RAS, EGF can also
accomplish cytoskeletal changes and cell migration via RAC
and AF6. Thus RAS serve as a crucial signaling hub for the
convergence and divergence of signals by switching between
the GDP and GTP bound forms.
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Due to its central role in intracellular signal transduction and
malignant transformation, a plethora of drugs targeting RAS
proteins or RAS effector pathways have been developed with
the aim to either correct or eliminate aberrant RAS signaling.
Early observations documenting that posttranslational modifi-
cations such as farnesylation, C-terminal peptide cleavage, and
carboxymethylation are essential for oncogenic RAS mutants
directed the initial development of farnesylation inhibitors
targeting RAS. The first farnesyl transferase inhibitors (FTIs)
mimicked the structure of the CAAX peptidic motif of RAS
and/or the structure of the farnesyl substrate. Some FTIs initially
showed promising pharmacological properties such as low
ID50, pronounced tumor regression in animal models, high
membrane permeability and low toxicity. For example, the FTI
tipifarnib received FDA approval for the treatment of older
patients with myelodysplastic syndrome, and Phase III trials
suggest that tipifarnib might also be a drug of choice for
treatment of older patients with acute myeloid leukemia [165].
Surprisingly, oncogenic RAS was not inhibited by FTIs and was
geranylgeranylated by the related geranylgeranyl transferase I
upon FTI exposure [166]. Thus although initially developed as
RAS inhibitors with promising results in animal tumor models,
FTIs seem to act via off-target inhibition of hitherto unidentified
substrate(s).
The repair of defective GTPase activity of mutant RAS by
GTP derivatives bearing residues required for GTP hydrolysis
has been reported [167,168]. However, this avenue of RAS
inhibition still awaits additional investigation to solve its major
problems, such as specificity or transport of compounds
modified by triphosphates through biological membranes.
The development of drugs inhibiting the interaction of RAS
with its effectors [169], immunological approaches and mutant-
specific siRNAs are also still in their infancies [165]. In
contrast, a couple of novel approaches are trying to target
aberrant RAS signaling by the inhibition of its downstream
effector pathways. For example, inhibition of MEK by CI-1040
stopped the growth of some cell lines expressing Q61R NRAS
[170]. Also the inhibition of MEK was surprisingly efficient for
cell lines harboring the V600E B-RAF mutation [170].
However, another study demonstrated that certain tumor cell
lines may develop resistance to CI-1040 by increasing
endogenous KRAS expression [171]. It is expected that despite
the inherent problems with RAS as a target, the ongoing
development of RAS pathway inhibitors will lead to additional
therapies in future, which in combination with a precise
molecular classification of tumors and additional classical
treatment modalities will add in to the ultimate goal of all tumor
therapies, which is complete and irreversible remission.
8. Novel avenues of RAS research
8.1. Regulating RAS by microRNAs
The observation that RAS is directly regulated by micro-
RNAs (miRNAs) added a new facet to the regulation of RAS[172]. MicroRNAs are small, non-coding RNAs modulating the
expression of target mRNAs at a post-transcriptional level
[173]. They are involved in the regulation of a wide variety of
cellular processes. It was estimated that the number of human
miRNAs is as high as 1000 [174] and that miRNAs may
regulate approximately 30% of all genes [175]. One of the
earliest reports linking miRNAs to cancer described that two
miRNAs, miR-15 and miR-16, are frequently deleted in chronic
lymphocytic lymphoma patients [176]. In the meantime, more
publications have appeared and proven that either the
deregulated expression or mutations of miRNAs are linked to
cancer and that miRNAs may function either as tumor
suppressors or oncogenes [177–179].
In 2005, it was discovered by in silico analysis that let-60,
the C. elegans ortholog of the RAS oncogenes, harbors let-7
target sites in its 3′-untranslated region (UTR) [172]. let-7 is a
heterochronic switch gene, whose loss causes reiterations of
larval cell fates in the adult, whereas overexpression of let-7
evokes premature expression of adult fates during larval stages
[180]. It encodes a 22 nucleotide RNA negatively regulating the
expression of protein-coding genes that contain regions of
complementarity in their 3′-UTRs by target mRNA degradation
[181]. Using various experimental strategies Slack went on and
proved that the amount of let-60/RAS is regulated by let-7
family members in the context of vulva development and in
human cell lines [172]. Since various let-7 family members
have been mapped to chromosomal regions frequently deleted
in lung tumors [182], and let-7 expression was reported being
reduced in lung tumors in association with shortened post-
operative survival [183], microarray analysis was performed on
tumor and matched adjacent non-tumor tissue from cancer
patients. Relative let-7 expression was reduced in 12 of 12 lung
cancers, 4 of 6 colon cancers and 2 of 3 breast cancers and
increased RAS protein levels were correlated with reduced let-7
expression [172]. let-7 is also part of a unique miRNA
expression profile that may be applicable as diagnostic and
prognostic marker for human lung cancer [184].
In summary, all data implicate that let-7 is a bona fide tumor
suppressor – at least in lung tumors – and that its effect is
mediated at least partially at the post-transcriptional level via
down-regulation of RAS expression. It remains to be addressed
(1) whether there are additional let-7 targets in lung tumorigen-
esis, (2) at which phase of tumor development and by which
mechanism let7 is downregulated, and (3) what is the overall
contribution of let7 to lung tumorigenesis?
8.2. Somatic and germline mutations in Human RAS genes
As mentioned above, RAS proteins possess multiple
functions, which differ depending on factors such as species,
genetic background, tissue or cell type and microenvironment.
As diverse as the regular functions of RAS proteins are as
diverse are their contributions to malignant phenotypic conver-
sion. RAS family members are involved in the execution of
almost any step in models of multi-step tumorigenesis [185] or,
in other words, contribute to each hallmark of cancer [186]. It
has been calculated that RAS is oncogenically activated in more
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residues 12, 13, 59 and 61, with positions 12 and 61 being the
most common [35]. By August 2006 the frequency of somatic
mutations in the main three RAS genes in the Catalogue of
Somatic Mutations in Cancer [187] was: (1) HRAS: mutated in
approximately 4% of samples analyzed with the highest
frequency in salivary gland (20%), urinary tract (12%) and
cervix (9%). (2) KRAS: mutated in approximately 21.7% of
samples analyzed with the highest frequency in pancreas (59%),
biliary tract (32%), large intestine (30%), small intestine (27%)
and lung (19%). (3) NRAS: mutated in approximately 8.2% of
samples analyzed with the highest frequency in skin (17%),
nervous system (16%) and hematopoietic and lymphoid tissues
(11%). Interestingly, a comparison of 12 activating amino acid
changes in KRAS at codons 12 and 13 revealed that the site and
the type of codon change vary significantly from tumor type to
tumor type [188]. For example, G13D KRAS is found almost
exclusively in soft tissue, stomach and thyroid tumors, whereas
G12D and G12V KRAS are more ubiquitously detected [188].
Unraveling the molecular mechanisms underlying the genetic
specificity and lineage dependency of the individual RAS
mutations is still an ongoing challenge in the field.
Although somatic point mutations in human RAS genes are
already known for many years, germline mutations in RAS as
well as in other components of RAS signaling pathways have
been detected only recently. These mutations have now been
proposed to be a unifying theme for a set of rare, phenotypically
overlapping developmental syndromes [189], which have been
summarized under the term “Neuro-Cardio-Facial-Cutaneous”
(NCDF) syndromes. These include Neurofibromatosis Type I
(NF1), Noonan syndrome (NS), LEOPARD syndrome, Cardio-
facio-cutaneous syndrome (CFC) and Costello syndrome (CS),
for recent reviews [190,191]. In general, patients with these
diseases are characterized by facial dysmorphisms, heart defects
and short stature. In addition, skin and genital malformations,
mental retardation and predisposition to certain malignancies
have been described [189]. De novo germline mutations have
been reported for example for KRAS in Noonan syndrome [192]
and in CFC [193], and for HRAS in Costello Syndrome [194–
197]. In addition, mutations of RAS effectors such as BRAF or
MEK1/2 have also been detected in CFC [198].
The consequences of RAS germline mutations found in
NCDF syndromes are less well characterized. For example, the
KRAS germline mutations V14I, T58I, and D153V in NS and
P34R, which are present in CFC patients, are rare in COSMIC.
Recombinant V41I and T58I proteins displayed defective
intrinsic GTP hydrolysis and impaired responsiveness to
GTPase activating proteins and hematopoietic progenitors
transfected with viruses encoding these mutants were hyper-
sensitive to growth factors [192]. In contrast, the heterozygous
germline HRAS missense mutations described in approximately
85% of CS patients are frequently found also in somatic tumors.
Whereas G12S HRAS is with 75% the most frequent HRAS
germline mutation, other mutations are represented at a lower
frequency [194–197]. Interestingly, more than 50% of patients
with the less frequent G12A mutation develop tumors including
rhabdomysarcoma, ganglioneuroblastoma and bladder carci-noma, whereas the overall malignancy frequency in all CS
patients with HRAS mutations is between 11 and 17% [197].
This indicates that the wild-type copy of HRAS, which is still
present in most of the CS patients, might antagonize the
function of mutated HRAS, which was already proposed in a
different context [96], and that the wild-type copy might cope
differently with germline mutations depending on the specific
mutation and the cell type involved. As described for some
germline KRAS mutations, HRAS mutations are hypersensitive
to growth factors, as shown by cell proliferation assays with
fibroblasts of selected CS patients [194].
In summary, the discovery of germline mutations in RAS and
other genes involved in RAS signaling was a major break-
through, but lots of open questions remain. (1) The number of
analyzed NCDF patients and the number of identified individual
germline mutations is still too low to draw far-reaching
conclusions. For example, most of the studies described data
from less than 100 patients. The same is true for the predicted
predisposition for malignancies in certain NCDF syndromes.
(2) The functional consequences of individual germline
mutations have to be addressed. Do these mutants engage
other signaling pathways than the respective wild-type proteins?
Are their ways to establish mouse models reflecting the human
phenotype? Why are these germline mutations primarily
dominant and the phenotypic effects with respect to increased
proliferation relatively mild? How do mutated RAS genes evoke
the complex phenotype pattern in NCDF patients and what is
the cause of the high variability in tissue-specific penetrance?
(3) Since there are still NCDF patients with no germline
mutation in the above mentioned genes, the mutational status of
other players involved in RAS signaling including scaffold
proteins needs to be analyzed in future.
8.3. Untangling the complexity of RAS function by large scale
proteomic and genomic approaches
Very early on in the 40 years of research on RAS it became
apparent that large-scale approaches are necessary to decipher
the full complexity of RAS function. So far only a few
proteomic approaches on RAS have been published. Cheng and
colleagues investigated mechanisms of RAS-mediated trans-
formation by proteomic profiling of G12V HRAS immortalized
human ovarian epithelial cell lines [199]. Using peptide mass
fingerprinting 16 out of 32 proteins found to be associated with
RAS-mediated transformation had not been linked previously to
RAS or RAS mediated transformation [199]. The protein targets
were classified according to function to processes such as
metabolism, redox balance, calcium signaling, apoptosis and
protein methylation. One key finding of this study was that
Caspase 4 maturation was blocked by G12V HRAS at the post-
translational level, which might partially explain, why HRAS
transformed cells evade apoptosis [199]. Earlier in 2006 the
group of Bakh dissected the targets of mutated HRAS proteins
in NIH 3T3 cells [200,201]. Either stable or tetracycline-
inducible cell lines expressing G12V or G12R HRAS were
generated, and their proteomes characterized by 2-DE,
quantitative imaging and MALDI-TOF MS. Overall, 213
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upon further characterization finally 64 polypeptides were
identified to be consistently deregulated by mutated HRAS (36
up-/28 down-regulated). Many HRAS targets identified were
associated with the cytoskeleton or molecular chaperones [200].
Unfortunately, the results provided were presented as common
changes in HRAS mutants and eminent questions, e.g. what are
the main differences between different HRAS mutants, were not
disclosed. Finally, the groups of Casal and Nebrada analyzed
the effects of G12V RAS on proteins differentially expressed at
cell membranes in either wild-type or p38α MAPK deficient
mouse embryo fibroblasts by 2D-DIGE coupled to MALDI-
TOF MS [202]. 42 differentially expressed proteins were
identified and seven proteins previously linked to transforma-
tion were verified by Western blot analysis. Whereas e.g.
prohibitin was down-regulated, the cytoplasmic tyrosine kinase
FAK2 and specific proteins involved in glucose metabolism or
mitochondrial respiration were up-regulated [202]. This pub-
lication demonstrated the feasibility of RAS proteome studies at
the sub-cellular level. Overall, proteomic approaches seem to
provide promising starting points with respect to RAS target
discovery and subsequent functional investigations.
Large-scale genomic expression profiling approaches for the
analysis of RAS function have been performed more frequently.
Initially, subtractive suppression hybridization was used for
genome-wide surveys of RAS transformation targets in rat
fibroblasts [203], thyroid cells [204] or ovarian epithelial cells
[205]. Common and distinct targets in cells transformed by
G12D NRAS, G12V KRAS or G12V HRAS were identified
and 61 putative RAS targets sensitive to MEK inhibition
described [203]. Di Lauro and coworkers concentrated on the
identification of 57 immediate early genes induced by activated
HRAS in differentiated, epithelial thyroid cells [204]. In G12V
KRAS transformed ovarian epithelial cells more than 200 genes
with altered expression were identified, 79 targets being
sensitive to inhibition of MEK/ERK or PI3K [205]. A whole
range of studies has been using high-density microarrays of
tumor cell lines or tumor xenograft tissues to detect oncogenic
RAS-dependent transcriptional changes. For example, 584
upregulated genes have been identified in an in vitro model of
human pancreatic duct epithelial carcinogenesis, which is
dependent on G12V KRAS [206]. The transcriptional effects
of G13D KRAS in combination with increased hepatocyte
growth factor signaling were evaluated in a model of human
colorectal cancer [207]. 139 differentially expressed genes were
identified in human melanoma cell lines carrying the Q61R
NRAS mutation [208]. Although these publications provide
hundreds of targets for specific RAS mutations in various in
vitro and in vivo tumor scenarios, further in-depth functional
analysis and independent confirmation by standardized array
technologies and post-array computational analysis is often
missing.
Another approach using microarray methods is to detect
expression signatures specific for certain tumors and/or RAS
mutants. This might be informative in the future for the
evaluation of clinical cancer outcome or patient management.
For example, Tyler Jacks and colleagues identified a G12DKRAS expression signature by cross-species gene expression
analysis of mouse and human lung tumors [209]. This signature
encompasses a set of 89 genes, which are indicative of KRAS
mutations and provide a source of novel potential effectors of
oncogenic KRAS activity in human cancer [209]. Also,
oligonucleotide array analysis of 20 different samples isolated
from human colorectal cancer patients with either BRAF or
KRAS mutation revealed an expression pattern of 98 genes that
is able to distinguish between BRAF and KRAS mutant groups
[210]. Out of these signatures for various tumor types it will be
important to identify those targets that are relevant for oncogene
addiction, a phenomenon describing the acquired dependence
of tumor cells on an activated oncogene for their survival and/or
proliferation [116,211,212]. Analyses of this type may provide
molecular targets for future therapeutic approaches by targeting
mutation-specific events in tumorigenesis.
Eric Holland and colleagues also performed microarray-
based assays to analyze how oncogenic RAS and AKT
signaling contribute to glioblastoma [213]. It was demonstrated
that the main effect of KRAS/AKT signaling is not at the level
of transcription, but the differential recruitment of already
transcribed specific mRNAs to polysomes. 426 individual
mRNAs were detected to be regulated by RAS/AKT at the level
of polysome loading within 2 h after blocking RAS/AKT
signals. The contribution of translational control to transforma-
tion by activated KRAS was recently independently confirmed
[214]. It needs now to be determined whether this translational
control is necessary or sufficient to induce or maintain tumor
formation [215]. In order to get a complete picture of RAS
function it may be necessary to look in detail not only at the
level of transcription and translation but also on additional
aspects of RAS regulation at a global scale. For example, a
genome-wide study on RAS-dependent miRNA expression
profiles in various human tumors is so far missing.
8.4. RAS and tumor stem cells
Sophisticated mouse tumor models have been generated and
have contributed significant insights into the isoform-specific
actions of mutated RAS genes, for comprehensive reviews
[1,216,217]. Due to species-specific differences and lack of full
correspondence to the human phenotype these models have to
be treated with caution. However, one major outcome of these
studies was that the given cellular context is of special
importance for tumor development and maintenance [218],
and the hypothesis was raised that certain RAS induced tumors
developed from stem cells or stem cell-like progenitor cells
[216]. For example, Tyler Jacks and colleagues isolated
bronchioalveolar stem cells (BASCs) exhibiting self-renewal
and multipotency in clonal assays [219] Conditional expression
of G12D KRAS in these BASCs in vitro or in vivo resulted in an
expansion of BASC number and subsequent differentiation
along the alveolar lineage. In naphthalene-treated mice expres-
sing activated KRAS an increase of size and number of lung
tumors were noted. The authors suggested that the microenvir-
onment conditions synergize with activated KRAS and claimed
that they have found the target cell population, from which
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activated RAS to different stem and progenitor cells of the skin
resulting in different types of benign and malign tumors
suggested that the nature of the cell in which tumor initiation
occurs and its microenvironment are main determinants of the
malignant potential (discussed in [220]). In this context it is also
noteworthy that mouse embryonic stem cells express a RAS-
like gene called ERAS, which is important for the tumor-like
properties of these cells [6] and that expression of activated
MRAS in hematopoietic stem cells initiated leukemogenic
transformation, immortalization and preferential generation of
mast cells [221]. Future studies have to address whether other
stem cell populations are also prone to RAS transformation and
by which mechanisms RAS-dependent tumorigenesis is
initiated. It is also conceivable that therapeutic approaches
will be developed that aim to suppress RAS-dependent tumor
formation by influencing the respective microenvironment.
9. Concluding remarks
The first cellular RAS oncogene was cloned in 1982 and
recently the Beatson Institute for Cancer Research in Glasgow,
UK has successfully organized a wonderful meeting on RAS
signaling and cancer to commemorate 24 years of intense RAS
research. There is an old saying that “familiarity breeds
contempt”, which is however not true in the context of RAS
research. The field has grown tremendously in the past years
with more than 150 family members and as many as 10 effector
pathways have been identified so far for RAS alone. The
functional interplay of many of these effector pathways needs to
be worked out in future in more detail. Apart from the effector
cascades identified, the RAF/MEK/ERK pathway as well as the
PI3K pathway still happened to be the most valuable targets for
cancer therapy. The recent identification of RalGEFs as crucial
regulators of human cell transformation has opened up a new
window in the search for new targets for therapeutic interven-
tion. The use of large-scale RNA interference libraries shows
considerable promise in quickly uncovering the crucial
components of RAS induced signaling cascades. The recent
discovery that RAS oncogene expression is modulated by
microRNAs has added a new facet to RAS research. In the days
to come, microRNAs regulating other downstream targets of the
RAS signaling cascades will be deciphered as well. There is no
doubt that these studies will keep up the momentum and
excitement of this ever growing field of RAS biology, thereby
retaining RAS at the heart of cancer research for the next
decades. Finally it is befitting to quote the concluding lines from
Robert Frost's famous poem:
The woods are lovely, dark, and deep, But I have promises
to keep, And miles to go before I sleep, And miles to go
before I sleep.Acknowledgements
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